The basic biology of NK cells and its application in tumor immunotherapy DOI Creative Commons
Pan Jiang,

Shaoze Jing,

Gaohong Sheng

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 16, 2024

Natural Killer (NK) cells play a crucial role as effector within the tumor immune microenvironment, capable of identifying and eliminating through expression diverse activating inhibitory receptors that recognize tumor-related ligands. Therefore, harnessing NK for therapeutic purposes represents significant adjunct to T cell-based immunotherapy strategies. Presently, strategies encompass various approaches, including adoptive cell therapy, cytokine antibody-based therapy (enhancing ADCC mediated by cells, engagers, checkpoint blockade therapy) utilization nanoparticles small molecules modulate anti-tumor functionality. This article presents comprehensive overview latest advances in immunotherapy, with aim offering insights methodologies clinical treatment cancer patients.

Language: Английский

CAR-NK cells for cancer immunotherapy: from bench to bedside DOI Creative Commons
Leisheng Zhang, Meng Yuan, Xiaoming Feng

et al.

Biomarker Research, Journal Year: 2022, Volume and Issue: 10(1)

Published: March 18, 2022

Abstract Natural killer (NK) cells are unique innate immune and manifest rapid potent cytotoxicity for cancer immunotherapy pathogen removal without the requirement of prior sensitization or recognition peptide antigens. Distinguish from T lymphocyte-based cythotherapy with toxic side effects, chimeric antigen receptor-transduced NK (CAR-NK) adequate to simultaneously improve efficacy control adverse effects including acute cytokine release syndrome (CRS), neurotoxicity graft-versus-host disease (GVHD). Moreover, considering inherent properties cells, CAR-NK “off-the-shelf” product satisfying clinical demand large-scale manufacture attribute cytotoxic effect via both cell receptor-dependent CAR-dependent signaling cascades. In this review, we mainly focus on latest updates cell-based tactics, together opportunities challenges immunotherapies, which represent paradigm boosting system enhance antitumor responses ultimately eliminate malignancies. Collectively, summarize highlight auspicious improvement in will benefit preclinical investigations adoptive immunotherapy.

Language: Английский

Citations

134
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment DOI
Nicole Kirchhammer, Marcel P. Trefny, Priska Auf der Maur

et al.

Science Translational Medicine, Journal Year: 2022, Volume and Issue: 14(670)

Published: Nov. 9, 2022

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, resistance to ICB occurs frequently due tumor-intrinsic alterations or extrinsic factors in the tumor microenvironment. This Viewpoint aims give an update on recent developments immunotherapy for solid tumors and highlights progress translational research clinical practice.

Language: Английский

Citations

117
CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy DOI Creative Commons
Kaveh Hadiloo, Safa Tahmasebi, Abdolreza Esmaeilzadeh

et al.

Cancer Cell International, Journal Year: 2023, Volume and Issue: 23(1)

Published: May 8, 2023

Abstract Today, cancer treatment is one of the fundamental problems facing clinicians and researchers worldwide. Efforts to find an excellent way treat this illness continue, new therapeutic strategies are developed quickly. Adoptive cell therapy (ACT) a practical approach that has been emerged improve clinical outcomes in patients. In ACT, best ways arm immune cells against tumors by employing chimeric antigen receptors (CARs) via genetic engineering. CAR equips target specific antigens on tumor selectively eradicate them. Researchers have achieved promising preclinical with different using CARs. One potent seems be good candidate for CAR-immune Natural Killer-T (NKT) cell. NKT multiple features make them would powerful replacement T natural killer (NK) cells. cytotoxic various capabilities no notable side effects normal The current study aimed comprehensively provide latest advances CAR-NKT cancers.

Language: Английский

Citations

51
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors DOI Creative Commons
Kaveh Hadiloo,

Siavash Taremi,

Mahmood Heidari

et al.

Biomarker Research, Journal Year: 2023, Volume and Issue: 11(1)

Published: Nov. 28, 2023

Abstract Today, adoptive cell therapy has many successes in cancer therapy, and this subject is brilliant using chimeric antigen receptor T cells. The CAR with its FDA-approved drugs, could treat several types of hematological malignancies thus be very attractive for treating solid cancer. Unfortunately, the cannot functional cancers due to unique features. This treatment method harmful adverse effects that limit their applications, so novel treatments must use new cells like NK cells, NKT macrophage Among these innate features, are more tumor seem a better candidate prior methods. have vital roles microenvironment and, direct effect, can eliminate efficiently. In addition, being part immune system, attended sites. With high infiltration, modulations effective. review investigates last achievements CAR-macrophage future immunotherapy method.

Language: Английский

Citations

47
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment DOI Creative Commons
Alain E. Andrea, Andrada Chiron,

Sarah Mallah

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Feb. 8, 2022

During this last decade, adoptive transfer of T lymphocytes genetically modified to express chimeric antigen receptors (CARs) emerged as a valuable therapeutic strategy in hematological cancers. However, immunotherapy has demonstrated limited efficacy solid tumors. The main obstacle encountered by CAR-T cells malignancies is the immunosuppressive tumor microenvironment (TME). TME impedes trafficking and penetration installs an milieu producing suppressive soluble factors overexpressing negative immune checkpoints. In order overcome these hurdles, new engineering strategies were designed, potentiate recognition infiltration anti-cancer activity hostile TME. review, we provide overview major mechanisms used evade defenses critically expose most optimistic make cell therapy option for

Language: Английский

Citations

46
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy DOI Creative Commons
Marisa K. Kilgour, Donald Bastin, Seung‐Hwan Lee

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: May 2, 2023

Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have revolutionized treatment for several cancer types over the past decade. Despite this success, obstacles including high price tag, manufacturing complexity, and treatment-associated toxicities limited broad application of therapy. Chimeric natural killer cell (CAR-NK) offers a potential opportunity simpler more affordable “off-the-shelf” treatment, likely with fewer toxicities. Unlike CAR-T, CAR-NK therapies are still early development, few clinical trials yet reported. Given challenges experienced through development CAR-T therapies, review explores what lessons we can apply to build better therapies. In particular, explore importance optimizing immunochemical properties CAR construct, understanding factors leading product persistence, enhancing trafficking transferred cells tumor, ensuring metabolic fitness product, strategies avoid tumor escape loss. We also trogocytosis, an important emerging challenge that equally applies cells. Finally, discuss how these limitations already being addressed future directions may be possible.

Language: Английский

Citations

42
Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma DOI Creative Commons
Yan Peng, Wenqing Zhang, Yufeng Chen

et al.

Pharmacological Research, Journal Year: 2023, Volume and Issue: 188, P. 106656 - 106656

Published: Jan. 11, 2023

Mesenchymal-epithelial transition factor (C-Met) has been acknowledged as a significant therapeutic target for treating lung adenocarcinoma (LUAD). However, the potential application of chimeric antigen receptors (CAR)-modified natural killer (NK) cells targeting c-Met in LUAD is rarely explored. In this study, bioinformatic databases were searched and tissue microarray (TMA) was enrolled to investigate expression status prognostic role LUAD. Then, four types c-Met-CAR structures designed prepared. The engineering CAR-NK containing c-Met-CARs transfected, verified characterized. tumor-inhibitory c-Met-CAR-NK finally evaluated vitro vivo. results demonstrated that elevated confirmed high significantly associated with unfavorable prognosis C-Met-CAR-NK successfully constructed DAP10 CAR structure favorable stimulator NK cell activation. CCN4 co-stimulator exhibited strongest cytotoxicity compared other cells. Furthermore, also exerted prominent effect on xenograft tumor growth. Collectively, study suggests potent activation, CCN4-based immunotherapy may represent promising strategy treatment c-Met-positive

Language: Английский

Citations

27
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy DOI Open Access
Seungyong Shin,

Pyunghwajun Lee,

Jieun Han

et al.

Tissue Engineering and Regenerative Medicine, Journal Year: 2023, Volume and Issue: 20(3), P. 371 - 387

Published: March 3, 2023

Language: Английский

Citations

24
In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy DOI
Lei Peng, Paul Renauer, Giacomo Sferruzza

et al.

Nature Biotechnology, Journal Year: 2024, Volume and Issue: unknown

Published: June 25, 2024

Language: Английский

Citations

13
Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges DOI

Theodoros Pettas,

Sofia Lachanoudi,

Filippos F. Karageorgos

et al.

World Journal of Transplantation, Journal Year: 2025, Volume and Issue: 15(2)

Published: Feb. 21, 2025

Despite existing curative options like surgical removal, tissue destruction techniques, and liver transplantation for early-stage hepatocellular carcinoma (HCC), the rising incidence mortality rates of this global health burden necessitate continuous exploration novel therapeutic strategies. This review critically assesses dynamic treatment panorama HCC, focusing specifically on burgeoning role immunotherapy in two key contexts: HCC downstaging advanced to facilitate transplant candidacy. It delves into unique immunobiology highlighting tumor-mediated immune evasion mechanisms. Analyzing diverse immunotherapeutic approaches including checkpoint inhibitors, cytokine modulators, vaccines, oncolytic viruses, antigen-targeting antibodies, adoptive cell therapy, acknowledges limitations current diagnostic markers alpha-fetoprotein glypican-3 emphasizes need biomarkers patient selection monitoring. Exploring rationale neoadjuvant adjuvant research is actively exploring safety effectiveness through ongoing clinical trials. The further explores potential benefits challenges combining transplant, careful selection, meticulous monitoring, strategies mitigate post-transplant complications. Finally, latest findings from landscape future directions management, paving way optimizing improving long-term survival patients with challenging malignancy.

Language: Английский

Citations

1